1. Home
  2. TRC vs PRTC Comparison

TRC vs PRTC Comparison

Compare TRC & PRTC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Tejon Ranch Co

TRC

Tejon Ranch Co

N/A

Current Price

$19.03

Market Cap

476.6M

Sector

Finance

ML Signal

N/A

Logo PureTech Health plc

PRTC

PureTech Health plc

N/A

Current Price

$17.00

Market Cap

464.3M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
TRC
PRTC
Founded
1843
2015
Country
United States
United States
Employees
N/A
N/A
Industry
Real Estate
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
476.6M
464.3M
IPO Year
1995
N/A

Fundamental Metrics

Financial Performance
Metric
TRC
PRTC
Price
$19.03
$17.00
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
74.7K
4.4K
Earning Date
01-01-0001
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$37,830,000.00
N/A
Revenue This Year
$2.31
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
$8.09
Revenue Growth
N/A
N/A
52 Week Low
$15.04
$13.30
52 Week High
$19.39
$20.00

Technical Indicators

Market Signals
Indicator
TRC
PRTC
Relative Strength Index (RSI) 76.38 47.75
Support Level $15.60 $16.51
Resistance Level $19.20 $18.10
Average True Range (ATR) 0.54 0.49
MACD 0.08 -0.05
Stochastic Oscillator 86.56 39.80

Price Performance

Historical Comparison
TRC
PRTC

About TRC Tejon Ranch Co

Tejon Ranch Co is a diversified real estate development and agribusiness company committed to responsibly using its land and resources to meet the housing, employment, and lifestyle needs of Californians and create value for its shareholders. It has five segments namely Real Estate - Commercial/Industrial, Real Estate - Resort/Residential, Mineral Resources, Farming, and Ranch Operations.

About PRTC PureTech Health plc

PureTech Health PLC, together with its subsidiaries, is a clinical-stage biopharma company developing medicines to modulate the adaptive human system. The company is focused on developing and commercializing differentiated medicines for devastating diseases, including inflammatory, immunological conditions, intractable cancers, lymphatic & gastrointestinal diseases, and neurological and neuropsychological disorders, among others. Its drug development pipeline consists of Deupirfenidone (LYT-100), for the potential treatment of idiopathic pulmonary fibrosis (IPF), LYT-200, SPT-300, an oral drug for depressive disorder, SPT-320, and others. The company's operating segments include Parent Companies & Other, which derives key revenue, Wholly-Owned Programs, and Controlled Founded Entities.

Share on Social Networks: